Adult-Onset Kaposiform Hemangioendothelioma with Early Kasabach-Merritt Phenomenon
Keywords:
Vascular tumor, Kaposiform hemangioendothelioma, Kasabach-Merritt phenomenonAbstract
Kaposiform hemangioendothelioma (KHE) is a rare, locally aggressive, vascular tumour with a peak onset within the first year of life. The condition is extremely rare in adulthood, with fewer than 40 cases of adult KHE reported worldwide. A common feature is a single cutaneous erythematous papule, plaque, nodule or tumour with a soft tissue mass on the extremities. Extracutaneous locations such as retroperitoneum muscle, bone, and thoracic cavity can occur and lead to compressive effects or the life-threatening consumptive coagulopathy known as Kasabach-Merritt phenomenon (KMP) which has high morbidity rates. The pathogenesis of KHE involves genetic and environmental factors, the vascular endothelial growth factor-3 axis, and angiopoietin-2 signalling, resulting in dysregulation of angiogenesis and lymphangiogenesis. The diagnosis of KHE requires clinical, histopathological, haematological, and imaging information.
Here, we report a case of a 59-year-old patient presented with solitary painful erythematous to purplish plaque at the left forearm for 4 months. A complete blood count showed profound thrombocytopenia (21,000 cells/mm3). Coagulogram, fibrinogen and D-dimer were within normal limits. Magnetic resonance imaging revealed mild superficial vein dilatation and subcutaneous fat in the lesion without intramuscular or deep-structure involvement. She was diagnosed with adult onset KHE with early KMP. After a discussion with haematologists, prednisolone (1 mg/kg/day) with topical tacrolimus was initiated as the patient could not afford oral sirolimus. She gradually responded, with a decrease in pain and lesion size and a normal platelet count.
References
Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. Am J Surg Pathol 1993;17:321-8.
Ji Y, Chen S, Yang K, Xia C, Li L. Kaposiform hemangioendothelioma: current knowledge and future perspectives. Orphanet J Rare Dis 2020;15:39.
Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 2013;162:142-7.
Vashi P, Abboud E, Bier-Laning, Gupta D. Adult-onset Kaposiform hemangioendothelioma of the tongue: case report and review of the literature. Curr Oncol 2016;23:e517-20.
Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin- TIE pathway. Nat Rev Drug Discov 2017;16:635-61.
Jiang RS, Hu R. Successful treatment of Kasabach-Merritt syndrome arising from kaposiformhemangioendothelioma by systemic corticosteroid therapy and surgery. Int J Clin Oncol 2012;17:512-6.
Ji Y, Yang K, Peng S, et al. Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon. Br J Dermatol 2018;179:457-63.
Drolet BA, Trenor CC 3rd, Brandão LR, et al. Consensus-derived practice standards plan for complicated Kaposiform Hemangioendothelioma. J Pediatr 2013;163:285-91.
Gruman A, Liang MG, Mulliken JB, et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon. J Am Acad Dermatol 2005;52:616-22.
Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol 2000;42:225-35.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Thai Journal of Dermatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใดๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นลิขสิทธิ์ของวารสารฯ หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใดๆ จะต้องได้รับอนุญาตเป็นลายลักอักษรจากบรรณาธิการวารสารโรคผิวหนังก่อนเท่านั้น